The respiratory research team at Bradford Teaching Hospitals has put itself on the map after recruiting European and global-first patients in two pioneering medical trials.
The trust says that thanks to a renowned international reputation in respiratory medicine, pharmaceutical giant GSK has chosen the Bradford Institute for Health Research (BIHR) to be the first unit worldwide to test its new vaccine for Chronic Obstructive Pulmonary Disease (COPD) patients.
The multi-centre trial aims to assess whether the vaccine offers protection against a bacterium which commonly causes a worsening in the condition of patients with COPD.
The team have also recruited a Europe-first patient in the Andhi study into severe asthma.
Dr Dinesh Saralaya, Consultant Respiratory Physician and Associate Director of Research at BIHR, said: “In this study there will be 1,000 patients recruited worldwide, and we will recruit between three and five patients.
“Our Clinical Trails Unit has recruited the first patient in the whole of Europe which is a big achievement. They have chosen Bradford because of our reputation for recruiting very well into several asthma trials in the past. But support from our research and development department has helped us achieve this.”